Lactobacillus brevis SBC8803 and Improved Liver Biomarkers

• Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.

  • 2016-12-01
  • Review
  • American journal of physiology. Gastrointestinal and liver physiology 311(6)
  • • Sena Bluemel
    • Brandon Williams
    • Rob Knight
    • Bernd Schnabl

  • PubMed: 27686615
  • DOI: 10.1152/ajpgi.00245.2016

  4 Insights on

  • Improved Liver Biomarkers

  • Low evidence

  products secreted by Lactobacillus- and microbiota-derived metabolites, such as fatty acids and antioxidants, that could be used for precision medicine in the treatment of liver disease

  Effect

  Beneficial

  Effect size

  Small